Katsi V, et al. - Researchers analyzed contemporary data from the literature to determine the prevalence, pathophysiologic mechanisms, treatment implications, and preventive strategies of hypertension in patients under antineoplastic therapy. Increased odds for new-onset hypertension or labile hypertensive status in previous controlled patients was observed consistently in relation to several classes of antineoplastic drugs, including mainly vascular endothelial growth factor inhibitors, proteasome inhibitors, cisplatin derivatives, corticosteroids, or radiation therapy. As per a growing body of evidence, an increase in the rate of progression of hypertension has been observed with multiple antineoplastic agents. For improved clinical outcomes and sustained survival, physicians may need to balance the life-saving cancer treatment with the inflated risk of adverse cardiovascular events attributed to suboptimal management of hypertension.